179 related articles for article (PubMed ID: 19157266)
21. [The platelet defect in myeloproliferative disorder (author's transl)].
Delobel J
Nouv Rev Fr Hematol (1978); 1976; 16(3):443-6. PubMed ID: 1012918
[TBL] [Abstract][Full Text] [Related]
22. [Diagnostic algorithm in chronic myeloproliferative diseases (CMPD)].
Haferlach T; Bacher U; Kern W; Schnittger S; Haferlach C
Med Klin (Munich); 2007 Sep; 102(9):770-7. PubMed ID: 17879017
[TBL] [Abstract][Full Text] [Related]
23. Platelet physiology and abnormalities of platelet function (second of two parts).
Weiss HJ
N Engl J Med; 1975 Sep; 293(12):580-8. PubMed ID: 1097915
[No Abstract] [Full Text] [Related]
24. [Acquired changes in platelet function].
Lucia JF
Sangre (Barc); 1984; 29(4-C):798-810. PubMed ID: 6096973
[No Abstract] [Full Text] [Related]
25. [ATP and ADP of platelets in chronic myeloproliferative disorders and multiple myeloma].
Terada H; Ohshima M
Rinsho Ketsueki; 1989 Jan; 30(1):22-8. PubMed ID: 2716195
[TBL] [Abstract][Full Text] [Related]
26. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.
Teofili L; Giona F; Martini M; Cenci T; Guidi F; Torti L; Palumbo G; Amendola A; Foà R; Larocca LM
J Clin Oncol; 2007 Mar; 25(9):1048-53. PubMed ID: 17369568
[TBL] [Abstract][Full Text] [Related]
27. Rapid real-time PCR assay for detection of MPL W515L mutation in patients with chronic myeloproliferative disorders.
Ghaderi M; Strömberg O; Porwit A
Int J Lab Hematol; 2010 Feb; 32(1 Pt 2):122-6. PubMed ID: 19016916
[TBL] [Abstract][Full Text] [Related]
28. Phenotype and genotype in the myeloproliferative disorders.
Spivak JL
Eur J Haematol Suppl; 2007 Oct; (68):9-12. PubMed ID: 17727558
[No Abstract] [Full Text] [Related]
29. [Blood platelet function in chronic myeloid-type diseases. I. Myeloproliferative diseases].
Cieslar P; Matousová O
Vnitr Lek; 1987 Nov; 33(11):998-1009. PubMed ID: 3439041
[No Abstract] [Full Text] [Related]
30. Update on the impact of the JAK2 mutation on signalling pathways in myeloproliferative disorders.
Skoda R
Eur J Haematol Suppl; 2007 Oct; (68):5-8. PubMed ID: 17727557
[No Abstract] [Full Text] [Related]
31. MPL W515 and JAK2 V617 mutation analysis in patients with refractory anemia with ringed sideroblasts and an elevated platelet count.
Steensma DP; Caudill JS; Pardanani A; McClure RF; Lasho TL; Tefferi A
Haematologica; 2006 Dec; 91(12 Suppl):ECR57. PubMed ID: 17194663
[TBL] [Abstract][Full Text] [Related]
32. [Selected parameters of blood platelet function in patients with myeloproliferative syndrome].
Zuk E
Ann Acad Med Stetin; 1998; 44():137-54. PubMed ID: 9857536
[TBL] [Abstract][Full Text] [Related]
33. Inherited traits affecting platelet function.
Salles II; Feys HB; Iserbyt BF; De Meyer SF; Vanhoorelbeke K; Deckmyn H
Blood Rev; 2008 May; 22(3):155-72. PubMed ID: 18180086
[TBL] [Abstract][Full Text] [Related]
34. [Summary of pathophysiology and diagnosis of patients with platelet abnormality].
Wada H; Asakura H
Rinsho Byori; 2009 May; 57(5):474-6. PubMed ID: 19522256
[TBL] [Abstract][Full Text] [Related]
35. Erythromelalgia and thrombocythemia: a disease of platelet prostaglandin metabolism--thesis, Rotterdam, 1981.
Michiels JJ
Semin Thromb Hemost; 1997; 23(4):335-8. PubMed ID: 9263349
[No Abstract] [Full Text] [Related]
36. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
Bellucci S; Michiels JJ
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
[TBL] [Abstract][Full Text] [Related]
37. Defective platelet beta-N-acetyl hexosaminidase content and release in chronic myeloproliferative disorders.
Emiliani C; Ciferri S; Mencarelli S; Mezzasoma AM; Momi S; Orlacchio A; Gresele P
Platelets; 2006 Feb; 17(1):20-9. PubMed ID: 16308183
[TBL] [Abstract][Full Text] [Related]
38. [Blood platelet changes in myeloproliferative disorders].
D'Angelo G; Calvano D; Giardini C
Minerva Med; 1988 Oct; 79(10):853-7. PubMed ID: 3141845
[TBL] [Abstract][Full Text] [Related]
39. Biochemical and metabolic aspects of platelet dysfunction in chronic myeloproliferative disorders.
Pareti FI; Gugliotta L; Mannucci L; Guarini A; Mannucci PM
Thromb Haemost; 1982 Apr; 47(2):84-9. PubMed ID: 7101243
[TBL] [Abstract][Full Text] [Related]
40. Histological and molecular classification of chronic myeloproliferative disorders in the age of JAK2: persistence of old questions despite new answers.
Hussein K; Bock O; Kreipe H
Pathobiology; 2007; 74(2):72-80. PubMed ID: 17587878
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
